MEK inhibitors for the treatment of non-small cell lung cancer
Top Cited Papers
Open Access
- 5 January 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 14 (1), 1-12
- https://doi.org/10.1186/s13045-020-01025-7
Abstract
BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK signaling pathway. To date, agents that target RAS/RAF/MEK/ERK signaling pathway have been investigated in NSCLC patients harboring BRAF mutations. BRAF and MEK inhibitors have gained approval for the treatment of patients with NSCLC. According to the reported findings, the combination of MEK inhibitors with chemotherapy, immune checkpoint inhibitors, epidermal growth factor receptor-tyrosine kinase inhibitors or BRAF inhibitors is highly significant for improving clinical efficacy and causing delay in the occurrence of drug resistance. This review summarized the existing experimental results and presented ongoing clinical studies as well. However, further researches need to be conducted to indicate how we can combine other drugs with MEK inhibitors to significantly increase therapeutic effects on patients with lung cancer.Keywords
Funding Information
- Medical Science and Technology Foundation of Henan Province (No. 201601026)
- The National Natural Science Foundation of China (No. 81272600)
- Foundation for Distinguished Young Talents in Higher Education of Henan (No. 201082, No. 18HASTIT044)
- Provincial Secretariat for Science and Technological Development (No. 2011020155)
- Henan Provincial Research Program of Application Foundation and Advanced Technology (No. 112300410033)
- Science and Technology Department of Henan Province (No. 201601026)
- Jiangsu Agricultural Science and Technology Independent Innovation Fund (No. [2016]32)
- Wu Yingkai Foundation for Medical Research and Development (No. 320.6799.15018)
This publication has 73 references indexed in Scilit:
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersNature, 2013
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyThe Lancet Oncology, 2013
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid TumorsClinical Cancer Research, 2012
- Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In VivoPLOS ONE, 2010
- MEK1 mutations confer resistance to MEK and B-RAF inhibitionProceedings of the National Academy of Sciences of the United States of America, 2009
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of CancerCancer Research, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Conserved Docking Site Is Essential for Activation of Mammalian MAP Kinase Kinases by Specific MAP Kinase Kinase KinasesMolecular Cell, 2005
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003